MedTrace Logo

Pirfenidone for Progressive Fibrotic Sarcoidosis

NCT03260556 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-09-28

No results posted yet for this study

Summary

Study comparing pirfenidone versus placebo for patients with advanced fibrotic sarcoidosis

Conditions

  • Sarcoidosis, Pulmonary

Interventions

DRUG

Pirfenidone

Increasing doses

DRUG

Placebos

Increasing doses

Sponsors & Collaborators

  • Royal Brompton & Harefield NHS Foundation Trust

    collaborator OTHER

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Robert P Baughman, MD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-27
Primary Completion
2019-12-31
Completion
2020-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03260556 on ClinicalTrials.gov